Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Centessa Pharmaceuticals plc (CNTA) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and related exhibits. As a Nasdaq-listed issuer with ordinary shares and American Depositary Shares registered under Section 12(b) of the Exchange Act, Centessa files documents that describe material events, financing transactions, governance matters and other information relevant to CNTA shareholders.
Recent Forms 8‑K detail items such as underwriting agreements for public offerings of American Depositary Shares, an amended and restated at-the-market sales agreement, financial results for quarterly periods, and the clearance of an Investigational New Drug (IND) application for ORX142. Filings also cover outcomes of the company’s annual general meeting, including director elections, auditor re-appointment and share allotment authorities, as well as executive employment arrangements reported under Item 5.02.
Through this page, users can review how Centessa reports progress and risks around its clinical-stage orexin receptor 2 (OX2R) agonist pipeline, capital-raising activities, and other significant corporate actions. Forms 8‑K that reference press releases often include clinical and financial updates, while accompanying exhibits such as sales agreements, underwriting agreements and legal opinions provide additional detail on transaction structures and securities law matters.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, sections and implications, helping readers quickly understand complex documents such as offering-related 8‑Ks and governance disclosures. Investors can use this resource to monitor CNTA’s regulatory reporting history, track new filings as they appear on EDGAR in near real time, and identify information relevant to their own analysis of the company.
Centessa Pharmaceuticals plc outlines final arrangements with former Chief Executive Officer Saurabh Saha, M.D., Ph.D., following his previously disclosed departure effective January 1, 2026. On February 9, 2026, the company entered into an Advisory Agreement and a Separation Agreement with Dr. Saha.
Under the Advisory Agreement, Dr. Saha will provide advisory services for an initial six-month term, automatically continuing unless terminated, at an hourly fee of $376.00 plus reimbursed business expenses. The Separation Agreement provides vesting of equity grants scheduled to vest on or before February 2, 2026, with later-vesting equity forfeited, and an exercise period of three months after the advisory role ends.
The Separation Agreement also includes, subject to Compensation Committee approval, a bonus equal to 100% of Dr. Saha’s target bonus for the year ended December 31, 2025, and continued eligibility for applicable company benefit plans. These extended benefits replace other severance or noncompetition payments under prior agreements and are conditioned on a general release of claims becoming effective after a seven-business-day revocation period.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 10,999,793 shares of Centessa Pharmaceuticals plc common stock, representing 12.2% of the class. FMR LLC holds sole voting power over 10,988,411 shares and sole dispositive power over 10,999,793 shares.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over 10,999,793 shares but no voting power. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Centessa.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 8,894,939 shares of Centessa Pharmaceuticals plc common stock, representing 9.9% of the class as of the stated event date. FMR reports sole voting and dispositive power over these shares.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 8,894,939 shares but no voting power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, and that one or more other persons may receive dividends or sale proceeds, with no single such person holding more than five percent of the class.
Centessa Pharmaceuticals plc reported that its Chief Medical Officer, Stephen Kanes, received an equity grant in the form of restricted share units. On February 2, 2026, he was awarded 120,000 Ordinary Shares at a price of $0 per share, bringing his directly held beneficial ownership to 120,000 Ordinary Shares.
The award consists of RSUs issued under Centessa’s Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one Ordinary Share. The RSUs will vest and be settled in four equal annual installments, with the first installment vesting on February 2, 2027, aligning compensation with long‑term company performance.
Centessa Pharmaceuticals awarded its Chief Financial Officer, John J. Crowley, new equity incentives. He received 45,000 Ordinary Shares as restricted share units that vest in four equal annual installments starting on February 2, 2027. The company also granted a share option for 181,000 Ordinary Shares with an exercise price of $25.19, expiring on February 2, 2036. This option vests in 48 equal monthly installments, beginning on March 2, 2026. These grants increase his direct beneficial ownership to 45,000 shares and 181,000 options, aligning his compensation more closely with the company’s future share performance.
Centessa Pharmaceuticals plc’s Chief Accounting Officer, Raphael Deferiere, reported new equity awards. On February 2, 2026, he received 11,000 Ordinary Shares as Restricted Share Units at $0 cost, bringing his directly held Ordinary Shares to 11,000.
He was also granted a share option for 42,000 Ordinary Shares at an exercise price of $25.19 per share, expiring on February 2, 2036. These options vest in equal monthly installments over 48 months starting March 2, 2026, while the RSUs vest in four equal annual installments beginning February 2, 2027.
Centessa Pharmaceuticals' Chief Legal Officer J Iqbal Hussain reported multiple equity transactions in Centessa Pharmaceuticals plc Ordinary Shares. On January 30, 2026, he sold 1,010 Ordinary Shares at a weighted average price of $25.0109. On February 1, 2026, 7,780 shares were withheld to cover tax obligations tied to vesting restricted share units at $24.57 per share.
On February 2, 2026, he sold an additional 38,951 Ordinary Shares at a weighted average price of $25.151, and received 40,000 restricted share units that vest in four equal annual installments starting February 2, 2027, plus 20,000 restricted share units that vest on February 2, 2027. He also received a share option for 160,000 Ordinary Shares at an exercise price of $25.19, vesting monthly over 48 months starting March 2, 2026. After these transactions, he directly beneficially owned 117,645 Ordinary Shares and indirectly 5,500 Ordinary Shares through his spouse, in addition to the 160,000-share option.
Centessa Pharmaceuticals’ Chief Business Officer Gregory M. Weinhoff reported new equity compensation and related share withholding. On February 1, 2026, 14,158 ordinary shares were withheld at $24.57 each to cover taxes on vesting restricted share units, leaving 108,121 shares owned directly.
On February 2, 2026, he received 31,000 restricted share units at $0, bringing his direct holdings to 139,121 ordinary shares. These RSUs vest in four equal annual installments starting February 2, 2027. He also was granted a share option for 123,000 ordinary shares at an exercise price of $25.19, vesting in 48 equal monthly installments beginning March 2, 2026 and expiring February 2, 2036.
Centessa Pharmaceuticals’ Chief Executive Officer Mario Alberto Accardi reported routine equity compensation and related tax withholding transactions in the company’s ordinary shares.
On February 1, 2026, 2,915 ordinary shares were withheld by Centessa to cover tax obligations tied to restricted share unit vesting, leaving him with 175,886 shares held directly. On February 2, 2026, he received 68,000 restricted share units for no cash cost, increasing his directly held ordinary shares to 243,886. The RSUs vest in four equal annual installments starting February 2, 2027.
Also on February 2, 2026, he was granted a share option for 273,000 ordinary shares at an exercise price of $25.19 per share. The option vests in equal monthly installments over 48 months, with the first installment vesting on March 2, 2026. Following this grant, he beneficially owns 273,000 options directly. Each ordinary share may be represented by one American Depositary Share.
Centessa Pharmaceuticals Chief People Officer Karen M. Anderson reported routine equity compensation and related tax withholding. On February 1, 2026, the company withheld 10,606 Ordinary Shares at a price of
On February 2, 2026, she received 29,000 Restricted Share Units under the company’s 2021 Stock Option and Incentive Plan, bringing her direct Ordinary Share holdings to 72,716. These RSUs vest in four equal annual installments starting February 2, 2027. She was also granted a share option for 117,000 Ordinary Shares at an exercise price of